ClinicalTrials.gg
Active, not recruitingNCT07115069REFORMUpdated Jul 14, 2026

Comparison of Body Composition Changes With Weight Loss Interventions

An observational study in Obesity, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Vanderbilt University Medical Center · Observational

How we know · 5 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Obesity by Vanderbilt University Medical Center — 7 open to participants now, 12 under way, 1 of them phase 3. Obesity · Vanderbilt University Medical Center.

Started
2025
the only one that year
Observational
7 of 40
1 open now
Primary completion
2027-06
later than 4 of 11 live
Registered
37th of 40
by date

Among the 40 studies in Obesity by Vanderbilt University Medical Center, this one is the only one that started in 2025, is one of 7 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 37th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 40 studies in Obesity by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Obesity by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

This study is being done to compare the effects of a newer class of weight loss medications to weight loss surgery on the body's muscle, metabolism, and side effects over time. People with severe obesity often lose weight using either medications like GLP-1 receptor agonists (such as semaglutide or tirzepatide) or by having bariatric surgery, such as gastric bypass. While both approaches can lead to weight loss, they may affect the body in different ways.

The investigators are inviting adult patients who are planning to either start one of these weight loss medications or undergo gastric bypass surgery to join this study. Participants will be asked to complete four body composition scans (called DXA scans) over the course of a year-at the beginning of the study and again at 3, 6, and 12 months. These scans will help us measure changes in fat and muscle. Participants will also complete surveys and provide information on side effects, such as nausea or fatigue, that may affect their eating or activity levels.

The investigators' goal is to better understand how different weight loss treatments impact not just weight, but also muscle mass, energy levels, and side effects. This information may help doctors and patients choose the most appropriate treatment in the future.

Read the detailed description

Patients are benefiting from landmark advancements in obesity treatments with the advent of Glucagon-like Peptide 1 Receptor agonists (GLP1RA) such as semaglutide and tirzepatide, which achieve weight loss of 15-20% in clinical trials.2,4,21 However, numerous questions surround the safety and efficacy of GLP1RAs compared to established surgical interventions. Minimally Invasive gastric bypass (GB) remains the benchmark for obesity treatments, with superior weight loss of 25-35%, and an extensive body of literature demonstrating long-term safety and efficacy, with rare complications and dramatic improvements in obesity-related comorbidities and quality of life.22,23 To date, an absence of guidelines exists to guide patients and clinicians in appropriate selection of therapies for obesity, largely resulting from the lack of head-to-head comparison for safety and efficacy of these interventions.

GLP1RAs carry several risks potentially limiting their benefit. The appetite suppression induced by GLP1RAs may result in disproportionate skeletal muscle depletion, the magnitude of which remains incompletely characterized.24,25 Loss of skeletal muscle can lead to poorer functional outcomes despite weight loss, and may lead to sarcopenic obesity if weight regain occurs after drug cessation.7,10 Additionally, a majority of patients taking GLP1RAs report adverse gastrointestinal (GI) symptoms including nausea, vomiting, constipation and abdominal pain, with reported discontinuation rates of >50% in clinical practice.26-29 Furthermore, the significant cost of GLP1RAs (averaging $10,000-15,000 annually) has placed considerable strain on healthcare systems. Recent studies suggest long-term cost benefits of GB over GLP1RAs30, but more research is needed to further delineate the most effective strategy in terms of both clinical outcomes and economic impact.

This study aims to compare impact of GLP1RAs and GB on skeletal muscle composition, GI symptom profiles, and quality of life metrics. This study will also compare changes in GI symptoms and quality of life between patients undergoing laparoscopic versus robotic GB.

Specific Aim 1: Compare change in appendicular lean body mass (LBM) after GLP-1 receptor agonists \& gastric bypass at 3, 6, and 12 months. Utilizing Dual-Energy X-ray Absorptiometry (DXA) scans conducted prior to surgery or mediation initiation and 3-, 6-, and 12-months post-intervention, the investigators will quantify the ratio of LBM loss to total weight loss with GLP1RAs and GB surgery. The investigators hypothesize that GLP1RA treatment will result in greater proportional loss of LBM than GB after 12 months of treatment. Data will be analyzed using mixed-effects models accounting for baseline characteristics and intervention type.

Specific Aim 2: Compare GI symptoms changes and overall quality of life following gastric bypass vs GLP1RAs and investigate real-world tolerability of GLP1RAs. Utilizing the validated Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM), administered at baseline and monthly intervals for 6 months, this study will compare the trajectory and severity of GI symptoms between those receiving GLP1RA and those who undergo GB. The investigators hypothesize that GLP1RA treatment will result in higher (worse) PAGI-SYM scores than GB throughout the study period. Additionally, will measure Health Related Quality of Life (HRQOL) monthly from intervention to 6 months post-intervention and compare trajectory of overall HRQOL after GLP1RA and GB.

Specific Aim 3: Comparison of GI symptoms and quality of life changes at 3 and 6 mo with robotic surgery and GLP1RA therapies. The investigators will also study how robotic GB compares to GLP1RA therapy in terms of GI symptomatology and health-related quality of life (HRQOL). HRQOL will be assessed using the validated SF-36 and the obesity-specific IWQOL-Lite instruments at baseline, 3 months, 6 months, and 12 months.

03

Conditions studied

  • Obesity

Browse trials for

Keywords

  • obesity
  • GLP-1 receptor agonist
  • gastric bypass surgery
  • bariatric surgery
  • incretin
  • glucagon like peptide 1 receptor agonist
  • robotic surgery
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Participants seeking medical or surgical weight loss for class III obesity

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥35 and ≤60
  • Primary weight loss surgery (gastric bypass), or
  • Medical weight loss with GLP1RAs (Semaglutide or Tirzepatide)

Exclusion criteria

Exclusion Criteria:

  • Revisional gastric bypass (e.g. sleeve to bypass),
  • \<3 months of continuous use of GLP1RA,
  • Type 1 Diabetes,
  • Myocardial Infarction,
  • Unstable Angina or Heart Failure,
  • Stroke
  • Solid organ transplantation,
  • Systemic prior 28 days,
  • Uncontrolled Hypertension, (Systolic > 150, Diastolic > 90)
  • Untreated Hyperthyroidism
  • Chronic Kidney Disease (EGFR \< 60).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No

Groups and cohorts

  • GLP-1 Receptor Agonists Arm

    Patient recieving Glucagon Like Peptide 1 Receptor Agonists (GLP1RA) or incretin polyagonists.

    Drug: GLP-1 receptor agonist

  • Gastric Bypass surgery (laparoscopic)

    Patients undergoing gastric bypass laparoscopically

    Procedure: Gastric Bypass Surgery (laparoscopic)

  • Gastric Bypass surgery (robotic)

    Patients undergoing Gastric Bypass surgery robotically

    Procedure: Gastric Bypass Surgery (robotic)

Interventions

  • DrugGLP-1 MimeticStudies of GLP-1 MimeticGLP-1 Mimetic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Any FDA-approved GLP-1 receptor agonist

    Also known as: semaglutide, tirzepatide

  • ProcedureGastric Bypass Surgery (laparoscopic)

    Patients undergo laparoscopic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.

    Also known as: RNYGB

  • ProcedureGastric Bypass Surgery (robotic)

    Patients undergo robotic gastric bypass with a roux limb between 75 - 150 cm and biliopancreatic limb between 50 - 150 cm as determined by the primary surgeon.

    Also known as: RNYGB

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Skeletal Muscle Loss

    loss of skeletal muscle (reported as appendicular lean body mass (LBM) on DXA) as a percent total body mass loss from baseline to 6 months as determined by DXA

    Time frame: 6 months

  2. Skeletal Muscle Loss

    loss of skeletal muscle (reported as appendicular lean body mass (LBM) on DXA) as a percent total body mass loss from baseline to 12 months as determined by DXA

    Time frame: 12 months

  3. Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire

    Median Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM score). Scores are on a 6 point Likert scale 0 (none/absent) to 5 (very severe) symptoms.

    Time frame: 6 months

  4. Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire

    Median Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire (PAGI-SYM score). Scores are on a 6 point Likert scale 0 (none/absent) to 5 (very severe) symptoms.

    Time frame: 12 months

Secondary outcomes

  1. Incidence of 10% weight loss

    Number of patients achieving ≥10% total body weight loss

    Time frame: 6 months

  2. Incidence of 10% weight loss

    Number of patients achieving ≥10% total body weight loss

    Time frame: 12 months

  3. Incidence of 15% weight loss

    Number of patients achieving ≥15% total body weight loss

    Time frame: 6 months

  4. Incidence of 15% weight loss

    Number of patients achieving ≥15% total body weight loss

    Time frame: 12 months

  5. Grip Strength

    Change in Grip strength measured by Jamar Grip Strength Hydraulic Dynanometer.

    Time frame: 3, 6, and 12 months

  6. PAGI-SYM sub-scale scores

    Sub-scale scores: 1. heartburn/regurgitation, 2. nausea/vomiting, 3. postprandial fullness, 4. bloating, 5. upper and lower abdominal pain

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Any sharing of de-identified data for scientific dissemination (e.g., publications, presentations) will comply with federal guidance and institutional requirements.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: At least 5 years after study end

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Jun 2027, 22 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 22 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2025
First posted
Aug 11, 2025
StartActual
Aug 9, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07115069
Responsible party
Jason Samuels (Principal Investigator, Vanderbilt University Medical Center) — Principal investigator
First posted
Aug 11, 2025
Start date
Aug 9, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Jason M Samuels, MD
principal investigator · Vanderbilt University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion